Therapeutic Proteins and Oral Vaccines Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Other Applications), By Region, And By Segment Forecasts, 2024-2031
The Therapeutic Proteins and Oral Vaccines Market Size is valued at 239.91 Million in 2023 and is predicted to reach 436.26 Million by the year 2031 at a 8.1 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The rise in severe diseases such as cancer, diabetes, and autoimmune disorders has increased the demand for therapeutic proteins. These proteins are used for treating conditions where traditional small-molecule drugs are ineffective.
- There is a growing awareness between both healthcare professionals and the general public about the benefits of therapeutic proteins and vaccines in preventing and treating diseases. This increased awareness is driving demand for these products.
- North America dominated the market and accounted for a global revenue share in 2023.
- The manufacturing of therapeutic proteins and oral vaccines often involves complex processes, such as cell culture, purification, and formulation. Ensuring consistent product quality and scalability can be challenging, leading to production delays and cost overruns.

Therapeutic proteins are genetically engineered proteins that have a wide range of treatment applications. Therapeutic proteins are mainly prepared for pharmaceutical use. Oral vaccines are biologically prepared products, which are used in treating or preventing various infectious diseases. The increasing number of pharmaceutical drug developments or innovations is expected to drive the growth of the therapeutic protein and oral vaccine market in the near future.
Major driving factors of the therapeutic proteins and oral vaccines market are the increasing need for therapeutic proteins and oral vaccines, high prevalence of cancer diseases, rising number of clinical trials, increasing investments by key players for the development of promising therapies. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people are enhancing the growth of the therapeutic proteins and oral vaccines market. However, the high price of devices, complex procedures, lack of strict government laws are restraining the growth of this market.
Competitive Landscape
Some Major Key Players In The Therapeutic Proteins and Oral Vaccines Market:
- Abbott Laboratories,
- Amgen, Inc.,
- Biogen, Inc.,
- Eily, Lilly, and Company,
- Hoffmann-La Roche,
- Johnson and Johnson,
- Merck & Co.,
- Novo Nordisk,
- Pfizer, Inc.,
- Sanofi S.A.,
- Serum Institute of India Pvt. Ltd.,
- Emergent Biosolutions Inc.,
- TransAlgae,
- MigVax Ltd,
- Lumen Bioscience, Inc.,
Market Segmentation
The therapeutic proteins and oral vaccines market is segmented into Drug Class, Distribution Channels, Applications, and regions. The Drug Class segment is further bifurcated into Therapeutic Proteins and Oral Vaccines. Therapeutic Proteins are subdivided into Therapeutic Proteins, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Other Therapeutic Proteins. While, Oral Vaccines are subdivided into Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Other Oral Vaccines. In the coming future, therapeutic proteins will be in high scope due to their effective and fast results and rise in therapy innovations. By Distribution Channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies will upscale the market of therapeutic proteins and oral vaccines over the forecast period. In terms of Applications, the market can be divided into Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Other Applications. Oncology and Infectious diseases are the fastest-growing segments of this market due to the increasing prevalence of cancer and infectious diseases. Based on the region, the therapeutic proteins and oral vaccines market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America followed by Europe holds the maximum share of this market due to increased research and development expenditure, presence of significant market players and fast adaption of advanced technologies.
Recent Developments:
- In April 2024, Bharat Biotech along with Bilthoven Biologicals B.V. (BBio), a fully owned subsidiary of Serum Institute of India Pvt. Ltd. with headquarters in the Netherlands, announced a partnership to enhance the production and supply security of oral polio vaccines (OPV).By means of this partnership, BBIL and BBio shall acquire collectively the necessary regulatory approvals and licenses to manufacture OPVs for global distribution in India from medicinal substances produced at Bilthoven Biologicals in the Netherlands.
Therapeutic Proteins and Oral Vaccines Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 239.91 Million |
| Revenue Forecast In 2031 | USD 436.26 Million |
| Growth Rate CAGR | CAGR of 8.1 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Class, By Distribution Channel, By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, Lumen Bioscience, Inc., and Other Prominent Players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Therapeutic Proteins and Oral Vaccines Market Segmentation
Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Drug Class
- Therapeutic Proteins
- Growth Factors
- Fusion Proteins
- Monoclonal Antibodies
- Hormones
- Coagulation Factors
- Other Therapeutic Proteins
- Oral Vaccines
- Live Attenuated Vaccine
- Inactivated Vaccine
- Recombinant Vaccine
- Other Oral Vaccines
Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Applications
- Oncology
- Hematology
- Immunology
- Endocrinology
- Infectious Disease
- Cardiovascular Disease
- Other Applications
Global Therapeutic Proteins and Oral Vaccines Market Size (Value US$ Mn) & Forecasts and Trend Analyses, Based on Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,
- U.S.
- Canada
Europe Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Revenue (US$ Million) By Country,
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Therapeutic Proteins and Oral Vaccines Market Size is valued at USD 239.91 Million in 2023 and is predicted to reach USD 436.26 Million by the yea
The Therapeutic Proteins and Oral Vaccines Market is expected to grow at an 8.1 % CAGR during the forecast period for 2024-2031.
Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer